Phase 2/3Recruiting
An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis
- Sponsor
- Cellcolabs Clinical SPV Limited (Industry)
- Enrolment
- 140 planned
- Conditions
- Knee Arthritis Osteoarthritis
- Interventions
- Mesenchymal Stem Cells (MSC); Hyaluronic Acid (HA)
- Ages
- adults, older adults
- Registry
- NCT07542808
From the registry
StromaForte injection for knee OA
Primary outcomes
- To show that StromaForte single dose treatment provides superior pain reduction from baseline to 6 months post-injection compared to hyaluronic acid single dose treatment.